FGF-23 and Endothelial Dysfunction in Diabetic Proteinuric Patients

• Status: Completed
• Trial end date: 2009-04-01
• Target enrollment: 0
• Participant gender: All

Summary

There is no data about the effects of Renin angiotensin system blockage (RAS) on FGF23 and ADMA levels in diabetic patients with proteinuria. The aim of this study was to find out whether the beneficial effects of RAS blockage in diabetic proteinuria has any relation with the alteration of ADMA and FGF-23 levels. We searched for the effects of ACE inhibitor ramipril on the clinical and laboratory parameters of diabetic patients with proteinuria.

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Gulhane School of Medicine
• Treatments: Ramipril

Criteria

Inclusion Criteria:

• CKD stage 1 patients

• Older than 18 years of age

• Type 2 Diabetic patients

• Proteinuria

Exclusion Criteria:

• History of coronary artery disease

• Smokers

• Taking statins or renin-angiotensin blockers